|
WO2021029813A1
|
|
Preventing and treating hypoglycemia
|
|
US2020138920A1
|
|
Novel Combinations for Antigen Based Therapy
|
|
US2021113586A1
|
|
New use and methods of modulating immune responses
|
|
US2020384086A1
|
|
Gaba a receptor agonists for treatment of disorders influenced by dysfunction beta cells
|
|
US2020360496A1
|
|
Novel composition and use thereof
|
|
KR20200051737A
|
|
Genotype classification in diabetes treatment and prevention
|
|
EP3679373A1
|
|
Improved immunotherapy
|
|
WO2019059822A1
|
|
New formulation of gamma-aminobutyric acid
|
|
WO2017058074A1
|
|
Combination therapy using gliadin and gamma aminobutyric acid
|
|
WO2017034459A1
|
|
New use
|
|
RU2702632C2
|
|
New combinations for antigenic therapy
|
|
WO2005094877A2
|
|
Formulation of glutamic acid decarboxylase (gad65) and serum albumin
|
|
WO2006013457A2
|
|
Gad2 gene for possible treatment of nervous system disorders
|
|
EP1755631A2
|
|
Immunomodulation by a therapeutic medication intended for treatment of diabetes and prevention of autoimmune diabetes
|
|
EP1545598A2
|
|
Formulation of glutamic acid decarboxylase (gad65) and serum albumin
|
